Stick A Fork In Us…Party Is Over!

Quote












anonymous said:
What do you mean ?

Please explain.
Click to expand...
Our stock price has been falling since the downsize. Wall Street has no confidence in Amarin. Great drug horrible marketing! There was never any money to do exhibits or bring it in front of thoughtleaders. Amarin put too much money up front with hiring way too many reps and not having money to do speaker programs. Remote audio conferences don’t count!
 












anonymous said:
Our stock price has been falling since the downsize. Wall Street has no confidence in Amarin. Great drug horrible marketing! There was never any money to do exhibits or bring it in front of thoughtleaders. Amarin put too much money up front with hiring way too many reps and not having money to do speaker programs. Remote audio conferences don’t count!
Click to expand...

You think Amarin failed because they didn’t put enough money into SPEAKER PROGRAMS?! That’s the dumbest explanation I've ever heard offered on here and that’s saying something. They absolutely hired too many reps but the biggest problem was not adequately resourcing the relationships with managed care. This shit is a nightmare to get covered and if they weren’t so myopic they would’ve realized that the key to the success of a new drug is to drive Rx volume by any means necessary - which means eliminating any and all barriers to get it into a patient’s hands, I.e. ensuring that it’s covered with no PA. Obviously losing the damn patent exclusivity last year sealed their fate but if they had actual food coverage and had gotten equity in reducing CV risk by then, it wouldn’t have mattered as much and/or the company would’ve been acquired by a better run/better resourced company.

Thank god I’m gone from this cesspool of an organization and have moved on to far greener pastures. Worst job I ever had, worst boss I ever had, worst everything.
 












anonymous said:
You think Amarin failed because they didn’t put enough money into SPEAKER PROGRAMS?! That’s the dumbest explanation I've ever heard offered on here and that’s saying something. They absolutely hired too many reps but the biggest problem was not adequately resourcing the relationships with managed care. This shit is a nightmare to get covered and if they weren’t so myopic they would’ve realized that the key to the success of a new drug is to drive Rx volume by any means necessary - which means eliminating any and all barriers to get it into a patient’s hands, I.e. ensuring that it’s covered with no PA. Obviously losing the damn patent exclusivity last year sealed their fate but if they had actual food coverage and had gotten equity in reducing CV risk by then, it wouldn’t have mattered as much and/or the company would’ve been acquired by a better run/better resourced company.

Thank god I’m gone from this cesspool of an organization and have moved on to far greener pastures. Worst job I ever had, worst boss I ever had, worst everything.
Click to expand...


Spot on.
 






anonymous said:
Our stock price has been falling since the downsize. Wall Street has no confidence in Amarin. Great drug horrible marketing! There was never any money to do exhibits or bring it in front of thoughtleaders. Amarin put too much money up front with hiring way too many reps and not having money to do speaker programs. Remote audio conferences don’t count!
Click to expand...
Yup. You can’t just throw a bunch of reps out there and think sample drops are going to do anything. The training department really failed by not properly teaching reps how to actually “sell” the product. Also, too many managers here just riding the wave to tack a few more earning years before retirement. Maybe if you had any leadership skills or values, you’d help educate your district and drive sales. Great possibilities to do wonders here, but failed by lack of talent at all levels of management.
 






anonymous said:
Yup. You can’t just throw a bunch of reps out there and think sample drops are going to do anything. The training department really failed by not properly teaching reps how to actually “sell” the product. Also, too many managers here just riding the wave to tack a few more earning years before retirement. Maybe if you had any leadership skills or values, you’d help educate your district and drive sales. Great possibilities to do wonders here, but failed by lack of talent at all levels of management.
Click to expand...
 












anonymous said:
Our stock price has been falling since the downsize. Wall Street has no confidence in Amarin. Great drug horrible marketing! There was never any money to do exhibits or bring it in front of thoughtleaders. Amarin put too much money up front with hiring way too many reps and not having money to do speaker programs. Remote audio conferences don’t count!
Click to expand...
It’s just overpriced fish oil, man. C’mon, it’s putting lipstick on a pig. Go to Costco and buy you some fish oil supplements 500 for 19.99. It’s all from the same fish. The cost of vascepa will give you a heart attack.
 






anonymous said:
You think Amarin failed because they didn’t put enough money into SPEAKER PROGRAMS?! That’s the dumbest explanation I've ever heard offered on here and that’s saying something. They absolutely hired too many reps but the biggest problem was not adequately resourcing the relationships with managed care. This shit is a nightmare to get covered and if they weren’t so myopic they would’ve realized that the key to the success of a new drug is to drive Rx volume by any means necessary - which means eliminating any and all barriers to get it into a patient’s hands, I.e. ensuring that it’s covered with no PA. Obviously losing the damn patent exclusivity last year sealed their fate but if they had actual food coverage and had gotten equity in reducing CV risk by then, it wouldn’t have mattered as much and/or the company would’ve been acquired by a better run/better resourced company.

Thank god I’m gone from this cesspool of an organization and have moved on to far greener pastures. Worst job I ever had, worst boss I ever had, worst everything.
Click to expand...
 






Launching a branded fish oil with a generic fish oil was already on the market was mistake one. Failing to understand that the weak patent was likely to be invalidated was mistake two. No fault of the sales and marketing teams here who have tried their best, especially in the face of managed care formulary hurdles, which were 100% predictable. It is time to adjust price closer to the generic in the US and focus on profitability outside the US, wherever exclusivity still exists. Unfortunately the size and spend of the US sales and marketing organization is not supported going forward. You need to know when to fold them…!
 






anonymous said:
Launching a branded fish oil with a generic fish oil was already on the market was mistake one. Failing to understand that the weak patent was likely to be invalidated was mistake two. No fault of the sales and marketing teams here who have tried their best, especially in the face of managed care formulary hurdles, which were 100% predictable. It is time to adjust price closer to the generic in the US and focus on profitability outside the US, wherever exclusivity still exists. Unfortunately the size and spend of the US sales and marketing organization is not supported going forward. You need to know when to fold them…!
Click to expand...

50% correct. This is not fish oil and not sure patent loss was predictable, but agree need to cut sales force and price and focus on EU.
 






Common let’s speak truthfully.

And I quote the FDA news wire… Vascepa is derived from omega-3 fish oil and… It contains the ingredient icosapent ethyl, which is a highly purified and stable EPA ethylester… The main difference is that Vascepa only contains eicosapentaenoic acid (EPA), whereas other approved generic prescription and supplemental OTC fish oils contain both EPA and docosahexaenoic acid (DHA).
 












anonymous said:
Launching a branded fish oil with a generic fish oil was already on the market was mistake one. Failing to understand that the weak patent was likely to be invalidated was mistake two. No fault of the sales and marketing teams here who have tried their best, especially in the face of managed care formulary hurdles, which were 100% predictable. It is time to adjust price closer to the generic in the US and focus on profitability outside the US, wherever exclusivity still exists. Unfortunately the size and spend of the US sales and marketing organization is not supported going forward. You need to know when to fold them…!
Click to expand...

Fish oil. Snake oil.

What's the difference.
 












anonymous said:
Common let’s speak truthfully.

And I quote the FDA news wire… Vascepa is derived from omega-3 fish oil and… It contains the ingredient icosapent ethyl, which is a highly purified and stable EPA ethylester… The main difference is that Vascepa only contains eicosapentaenoic acid (EPA), whereas other approved generic prescription and supplemental OTC fish oils contain both EPA and docosahexaenoic acid (DHA).
Click to expand...
 






anonymous said:
Common let’s speak truthfully.

And I quote the FDA news wire… Vascepa is derived from omega-3 fish oil and… It contains the ingredient icosapent ethyl, which is a highly purified and stable EPA ethylester… The main difference is that Vascepa only contains eicosapentaenoic acid (EPA), whereas other approved generic prescription and supplemental OTC fish oils contain both EPA and docosahexaenoic acid (DHA).
Click to expand...
 






Top Bottom
Back
Quote